Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

• Status: Active, not recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or mild AD.

Secondary objectives are:

1. To evaluate in patients on T-817MA and placebo:

• cognitive function measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) and working memory and attention domain as measured by the Cognitive Functional Composite (CFC).

• AD-related biomarkers in CSF and plasma

• imaging analysis using volumetric magnetic resonance imaging (vMRI)

• alpha/theta ratio of the electroencephalogram (EEG)

2. To evaluate the safety of T-817MA by clinical laboratory tests and adverse events (AEs).

3. To evaluate the pharmacokinetics of T-817MA

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: FUJIFILM Toyama Chemical Co., Ltd.

Criteria

Key Inclusion Criteria:

• Female of non-childbearing potential or male, ages 50 to 80 years (inclusive)

• MCI due to AD or mild AD per NIA-AA diagnostic criteria (Jack et al., 2018), with MMSE 24 to 30 (inclusive)

• CSF results at Screening consistent with the presence of Aß and p-tau181 abnormality (≤1000 pg/ml for Aß, ≥19 pg/ml for p-tau181).

• Taking stable dose of AChE Inhibitor (donepezil, galantamine or rivastigmine) at least for 3 months prior to randomization, or not taking any AChE Inhibitors.

Key Exclusion Criteria:

• MRI of the brain within the previous 2 years that showed pathology that would be inconsistent with a diagnosis of AD

• Taking memantine

• Any contraindications to lumbar puncture

• Any contraindications to MRI